Associated Papers
The Influence of Genetics in the Early Development of Axial Postural Abnormalities in Parkinson's Disease.
Vico IAD et al.
Movement Disorders Clinical Practice, 2026
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.
Pitton Rissardo J et al.
Brain Sciences, 2025
The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging.
Rana A et al.
Acs Chemical Neuroscience, 2025
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.
Lange LM et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health.
Uytterhoeven V et al.
The Journal of Cell Biology, 2025
The α-Synuclein Seeding Amplification Assay for Parkinson's Disease.
Yi LX et al.
International Journal of Molecular Sciences, 2025
Mass spectrometry-based proteomics for biomarker discovery in the Drosophila model of Parkinson's disease.
Khan MR et al.
Neuroprotection (chichester, England), 2024
Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders.
Sidoryk-Węgrzynowicz M et al.
International Journal of Molecular Sciences, 2024
Impaired Sonic Hedgehog Responsiveness of Induced Pluripotent Stem Cell-Derived Floor Plate Cells Carrying the LRRK2-I1371V Mutation Contributes to the Ontogenic Origin of Lower Dopaminergic Neuron Yield.
Potdar C et al.
Stem Cells and Development, 2024
Astroglial activation: Current concepts and future directions.
Edison P
Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 2024
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.
Wang XL et al.
Cellular and Molecular Neurobiology, 2021
Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Franco R et al.
International Journal of Molecular Sciences, 2021
Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.
Madsen DA et al.
Cells, 2021
Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM et al.
Journal of Parkinson's Disease, 2021
Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.
Abe T et al.
Frontiers in Neurology, 2021
Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models.
Taoufik E et al.
Open Biology, 2018
Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention.
Briston T et al.
Biochemical Society Transactions, 2018
Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.
Dirr ER et al.
Behavioural Brain Research, 2018
Autonomic dysfunction in genetic forms of synucleinopathies.
Chelban V et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2018
α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton.
Ordonez DG et al.
Neuron, 2018
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.
Zeng XS et al.
Frontiers in Aging Neuroscience, 2018
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Schneider SA et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2017
Diversity of astroglial responses across human neurodegenerative disorders and brain aging.
Ferrer I
Brain Pathology (zurich, Switzerland), 2017
Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.
Ottolini D et al.
Biological Chemistry, 2017
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.
Hernandez DG et al.
Journal of Neurochemistry, 2016
Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Van Rompuy AS et al.
Molecular Neurodegeneration, 2015
Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.
Van Rompuy AS et al.
Journal of Neuropathology and Experimental Neurology, 2014
Parkin plays a role in sporadic Parkinson's disease.
Dawson TM et al.
Neuro-degenerative Diseases, 2014
Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
Oaks AW et al.
Plos One, 2013
Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.
McNeill A et al.
Plos One, 2013
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
Wales P et al.
Journal of Parkinson's Disease, 2013
Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance.
Lonskaya I et al.
Plos One, 2013
PARK2 gene mutations in early onset Parkinson's disease patients of South India.
Padmaja MV et al.
Neuroscience Letters, 2012
The neuropathology of genetic Parkinson's disease.
Poulopoulos M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2012
Genetically engineered mouse models of Parkinson's disease.
Crabtree DM et al.
Brain Research Bulletin, 2012
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Kumar P et al.
Journal of Neurochemistry, 2012
Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation.
Huang Y et al.
Translational Neurodegeneration, 2012
Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction.
Ali SF et al.
International Journal of Environmental Research and Public Health, 2011
Parkinson's disease mouse models in translational research.
Antony PM et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2011
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
Yue Z et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2011
Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5).
Kalia LV et al.
Plos One, 2011
Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease.
Lee YJ et al.
Plos One, 2011
On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Daniëls V et al.
Neuro-signals, 2011
Mouse models of cognitive deficits due to alpha-synuclein pathology.
Magen I et al.
Journal of Parkinson's Disease, 2011
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Mice expressing mutant parkin exhibit hallmark features of Parkinson's disease.
Hart MP et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2009
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Olivares D et al.
International Journal of Molecular Sciences, 2009